title: Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial.
abstract: BACKGROUND
  This study is intended to evaluate the propensities of cilostazol to reduce the pulsatility index (PI) in patients with acute lacunar infarction using the serial transcranial Doppler (TCD) examinations.
  
  
  METHODS
  In a multicenter, randomized, double-blind, placebo-controlled trial, patients were randomly assigned to receive either placebo or 100 mg cilostazol twice a day as well as aspirin 100 mg a day. The primary outcomes were the changes of middle cerebral artery (MCA) and basilar artery (BA) PIs at 14 and 90 days from the baseline TCD study. This study is registered with ClinicalTrials.gov (NCT00741286).
  
  
  RESULTS
  Trial medication was given to 203 patients, with 100 receiving cilostazol and 103 receiving placebo, and 164 were included in the per-protocol analysis of the primary outcome. Results from the linear mixed model showed that significant effects were obtained for time-by-group interactions (p = 0.008 in right MCA, p = 0.015 in left MCA, p = 0.002 in BA), suggesting that changes of PIs from the baseline to the 90-day study were different across the groups.
  
  
  CONCLUSIONS
  Cilostazol further decreased TCD PIs at 90 days from baseline compared to placebo in acute lacunar infarction. This result may be related to pleiotropic effects, such as vasodilation, beyond its antiplatelet activity.
authors.affiliation: Department of Neurology at Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
authors.forename: Sang Won
authors.initials: SW
authors.lastname: Han
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Lee
authors.forename: Seo Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Jun Hong
authors.initials: JH
authors.lastname: Lee
authors.forename: Gyu Sik
authors.initials: GS
authors.lastname: Kim
authors.forename: Ok-Joon
authors.initials: OJ
authors.lastname: Kim
authors.forename: Im-Seok
authors.initials: IS
authors.lastname: Koh
authors.forename: Jong Yun
authors.initials: JY
authors.lastname: Lee
authors.forename: Seung-Han
authors.initials: SH
authors.lastname: Suk
authors.forename: Sung Ik
authors.initials: SI
authors.lastname: Lee
authors.forename: Hyo Suk
authors.initials: HS
authors.lastname: Nam
authors.forename: Won-Joo
authors.initials: WJ
authors.lastname: Kim
authors.forename: Seok Woo
authors.initials: SW
authors.lastname: Yong
authors.forename: Kyung-Yul
authors.initials: KY
authors.lastname: Lee
authors.forename: Jae Hyeon
authors.initials: JH
authors.lastname: Park
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D000077407:Cilostazol; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D063177:Pulse Wave Analysis; D059409:Stroke, Lacunar / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D017585:Ultrasonography, Doppler, Transcranial
chemical_list: D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol; D001241:Aspirin